{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:01:32Z","timestamp":1720382492500},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Celgene, Inc"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA16056"],"award-info":[{"award-number":["CA16056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Szefel Foundation"},{"name":"Leonard S. LoVullo Endowment for Leukemia Research"},{"name":"Nancy C. Cully Endowment for Leukemia Research"},{"name":"Babcock Family Endowment"},{"name":"Heidi Leukemia Research Fund"},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Teva Pharmacueticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.leukres.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T08:32:28Z","timestamp":1455611548000},"page":"44-48","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"43","author":[{"given":"Elizabeth A.","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Vigil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie A.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle M.","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"L. Bashaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Sperrazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Wetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2016.02.003_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.leukres.2016.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1080\/1042819021000006529","article-title":"The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature","volume":"43","author":"Leopold","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.003_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/jcm4040665","article-title":"Current approaches in the treatment of relapsed and refractory acute myeloid leukemia","volume":"4","author":"Ramos","year":"2015","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.leukres.2016.02.003_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults","volume":"135","author":"British Committee for Standards in Haematology","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2016.02.003_bib0025","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","article-title":"Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C","volume":"35","author":"Corsetti","year":"2011","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/j.leukres.2016.02.003_bib0030","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2016.02.003_bib0035","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2009-06-229351","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse","volume":"114","author":"Giles","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.02.003_bib0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0145-2126(99)00087-9","article-title":"A phase III comparison of high Dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study","volume":"23","author":"Karanes","year":"1999","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2016.02.003_bib0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.leukres.2016.02.003_bib0050","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1200\/JCO.2010.30.3339","article-title":"Dose escalation of lenalidomide in relapsed or refractory acute leukemias","volume":"28","author":"Blum","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.003_bib0055","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.003_bib0060","doi-asserted-by":"crossref","first-page":"434a","DOI":"10.1182\/blood.V114.22.1049.1049","article-title":"Lenalidomide (LEN) combined to intensive chemotherapy (IC) in AML and higher risk MDS with del 5q. Interim results of a phase I\/II study [abstract]","volume":"114","author":"Ades","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.003_bib0065","doi-asserted-by":"crossref","first-page":"620a","DOI":"10.1182\/blood.V122.21.620.620","article-title":"Lenalidomide (LEN) combined to intensive chemotherapy (IC) In AML and higher risk MDS with del 5q. Results of a phase I\/II study of the Groupe Francophone Des Myelodysplasies (GFM) [abstract]","volume":"112","author":"Ades","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.02.003_bib0070","first-page":"70","article-title":"Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities","volume":"2","author":"Dennis","year":"2013","journal-title":"Leuk. Res. Rep."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.003_bib0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1470-2045(06)70723-9","article-title":"Immunomodulating drugs for chronic lymphocytic leukaemia","volume":"7","author":"Chanan-Khan","year":"2006","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2016.02.003_bib0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/13543784.2013.758712","article-title":"Lenalidomide as a novel treatment of acute myeloid leukemia","volume":"22","author":"Chen","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6168","key":"10.1016\/j.leukres.2016.02.003_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.leukres.2016.02.003_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"7559","key":"10.1016\/j.leukres.2016.02.003_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2016.02.003_bib0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2012-05-428573","article-title":"Lenalidomide-mediated enhanced translation of C\/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia","volume":"121","author":"Hickey","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2016.02.003_bib0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2016.02.003_bib0110","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2016.02.003_bib0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.003_bib0120","series-title":"Clinical Trials in Oncology","first-page":"45","author":"Green","year":"2002"},{"issue":"31","key":"10.1016\/j.leukres.2016.02.003_bib0125","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2008.17.5554","article-title":"Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study","volume":"26","author":"Marcucci","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2016.02.003_bib0130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2009-07-229492","article-title":"P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808","volume":"116","author":"Kolitz","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2016.02.003_bib0135","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"25","key":"10.1016\/j.leukres.2016.02.003_bib0140","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Blum","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.003_bib0145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2016.02.003_bib0150","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1002\/cncr.26097","article-title":"Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia","volume":"117","author":"Wetzler","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2016.02.003_bib0155","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.leukres.2013.07.036","article-title":"Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age","volume":"37","author":"Vigil","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2016.02.003_bib0160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","article-title":"Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502","volume":"31","author":"Attar","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T14:25:26Z","timestamp":1600179926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":32,"alternative-id":["S0145212616300194"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed\/refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}